title: Antibody Drug Conjugates for Cancer Therapy.
abstract: Antibody drug conjugates (ADCs) constitute a family of cancer therapeutics designed to preferentially direct a cytotoxic drug to cells expressing a cell-surface antigen recognized by an antibody. The antibody and drug are linked through chemistries that enable release of the cytotoxic drug or drug adduct upon internalization and digestion of the ADC by the cell. Over 40 distinct ADCs, targeting an array of antigens and utilizing a variety of drugs and linkers, are undergoing clinical evaluation. This review primarily covers ADCs that have advanced to clinical investigation with a particular emphasis on how the individual targets, linker chemistries, and appended drugs influence their behavior.
authors.affiliation: Department of Molecular Oncology, Genentech, South San Francisco, California polakis.paul@gene.com.
authors.forename: Paul
authors.initials: P
authors.lastname: Polakis
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D065546:Drug Liberation; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates